JP2006510619A5 - - Google Patents

Download PDF

Info

Publication number
JP2006510619A5
JP2006510619A5 JP2004554020A JP2004554020A JP2006510619A5 JP 2006510619 A5 JP2006510619 A5 JP 2006510619A5 JP 2004554020 A JP2004554020 A JP 2004554020A JP 2004554020 A JP2004554020 A JP 2004554020A JP 2006510619 A5 JP2006510619 A5 JP 2006510619A5
Authority
JP
Japan
Prior art keywords
box
hmgb
polypeptide
group
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004554020A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006510619A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/037507 external-priority patent/WO2004046345A2/en
Publication of JP2006510619A publication Critical patent/JP2006510619A/ja
Publication of JP2006510619A5 publication Critical patent/JP2006510619A5/ja
Pending legal-status Critical Current

Links

JP2004554020A 2002-11-20 2003-11-20 抗炎症剤としてのhmgb断片の使用 Pending JP2006510619A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42784102P 2002-11-20 2002-11-20
US42784602P 2002-11-20 2002-11-20
PCT/US2003/037507 WO2004046345A2 (en) 2002-11-20 2003-11-20 Use of hmgb fragments as anti-inflammatory agents

Publications (2)

Publication Number Publication Date
JP2006510619A JP2006510619A (ja) 2006-03-30
JP2006510619A5 true JP2006510619A5 (https=) 2006-12-28

Family

ID=32329191

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004554020A Pending JP2006510619A (ja) 2002-11-20 2003-11-20 抗炎症剤としてのhmgb断片の使用

Country Status (6)

Country Link
EP (1) EP1569684A4 (https=)
JP (1) JP2006510619A (https=)
AU (1) AU2003294488B2 (https=)
CA (1) CA2506328A1 (https=)
NZ (1) NZ540067A (https=)
WO (1) WO2004046345A2 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303321B1 (en) 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US7304034B2 (en) 2001-05-15 2007-12-04 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
US7696169B2 (en) 2003-06-06 2010-04-13 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
WO2005025604A2 (en) * 2003-09-10 2005-03-24 The General Hospital Corporation Use of hmgb and hmgb fragments to decrease specific immune response
CA2882022A1 (en) 2003-09-11 2005-03-24 Walter Newman Monoclonal antibodies against hmgb1
PL1768677T3 (pl) * 2004-07-02 2009-01-30 Creabilis Therapeutics Spa Kwasy nukleinowe do leczenia patologii związanych z HMGB-1
WO2006012373A2 (en) * 2004-07-20 2006-02-02 Critical Therapeutics, Inc. Combination therapies of hmgb and complement inhibitors against inflammation
NZ553809A (en) * 2004-09-03 2010-03-26 Creabilis Therapeutics Spa Use of polypeptides obtained through systematic mutations of single amino acids of human and non-human box-A of HMGB1 to prevent and/or antagonize pathologies induced by HMGB1
US7585504B2 (en) * 2004-10-22 2009-09-08 Medimmune, Llc High affinity antibodies against HMGB1 and methods of use thereof
EP1899376A2 (en) * 2005-06-16 2008-03-19 The Feinstein Institute for Medical Research Antibodies against hmgb1 and fragments thereof
WO2007011606A2 (en) * 2005-07-18 2007-01-25 Critical Therapeutics, Inc. USE OF HMGBl ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY SKIN CONDITIONS
WO2007031100A1 (en) * 2005-09-14 2007-03-22 Ostini, Marco Active immunotherapy of life-threatening systemic inflammation
EP1957534A1 (en) * 2005-11-09 2008-08-20 Pharmexa A/S Therapeutic vaccines targeting hmgb1
AU2007296843C1 (en) 2006-09-15 2012-08-16 Creabilis Therapeutics S.P.A. Polymer conjugates of Box-A of HMGB1 and Box-A variants of HMGB1
PT2066339E (pt) 2006-09-18 2014-10-31 Texas A & M Univ Sys Composições e métodos de potenciar respostas imunes
WO2008099913A1 (ja) 2007-02-15 2008-08-21 Kumamoto University ヒトhmgb-1に特異的に結合する抗体を有効成分として含有する治療剤
ES2654542T3 (es) 2008-04-30 2018-02-14 Genomix Co., Ltd. Procedimiento de recolección de células funcionales in vivo con alta eficiencia
US11191786B2 (en) 2009-10-28 2021-12-07 StemRIM Inc. Agents for promoting tissue regeneration by recruiting bone marrow mesenchymal stem cells and/or pluripotent stem cells into blood
US8956618B2 (en) 2010-01-21 2015-02-17 The Texas A&M University System Vaccine vectors and methods of enhancing immune responses
NZ604412A (en) 2010-06-09 2015-01-30 Univ Arkansas Vaccine and methods to reduce campylobacter infection
EP2703487B1 (en) 2011-04-26 2018-06-27 Genomix Co., Ltd. Peptide for inducing regeneration of tissue and use thereof
AU2013335684B2 (en) 2012-10-25 2017-06-29 Osaka University Novel method for treating cardiac infarction using HMGB1 fragment
DK2913059T3 (en) 2012-10-25 2018-06-25 Genomix Co Ltd Hitherto UNKNOWN PROCEDURE FOR TREATMENT OF SPINE INJURY USING HMGB1 FRAGMENT
US9550825B2 (en) 2013-01-28 2017-01-24 Evec Inc. Humanized anti-HMGB1 antibody or antigen-binding fragment thereof
HUE047484T2 (hu) 2013-02-14 2020-04-28 Univ Arkansas Készítmények és eljárások eimeria elleni immunválasz fokozására vagy eimeria-fertõzés korlátozására
CA2906079C (en) 2013-03-15 2022-08-23 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to enteric pathogens
KR20190015712A (ko) 2016-05-03 2019-02-14 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 면역자극 및 항원 폴리펩티드를 포함하는 효모 백신 벡터, 및 그를 이용하는 방법
US11969459B2 (en) 2017-01-27 2024-04-30 StemRIM Inc. Therapeutic agent for cardiomyopathy, old myocardial infarction and chronic heart failure
AU2018236271B2 (en) 2017-03-15 2023-12-21 Research Institute At Nationwide Children's Hospital Composition and methods for disruption of bacterial biofilms without accompanying inflammation
CA3084013A1 (en) 2017-12-01 2019-06-06 StemRIM Inc. Ectodermal mesenchymal stem cells and method for producing same
WO2019107530A1 (ja) * 2017-12-01 2019-06-06 株式会社ステムリム 炎症性腸疾患の治療薬
WO2019156137A1 (ja) * 2018-02-08 2019-08-15 株式会社ステムリム 乾癬の治療薬
US12304933B2 (en) 2018-10-05 2025-05-20 StemRIM Inc. Disease treatment drug based on mesenchymal-stem-cell mobilization
SG11202103001PA (en) * 2018-10-05 2021-04-29 Res Inst Nationwide Childrens Hospital Hmgb1 protein derivatives for the removal of biofilms cross-reference to related application
CN111743890A (zh) * 2019-03-26 2020-10-09 深圳先进技术研究院 水绫霉素或其衍生物的用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303321B1 (en) * 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
CA2296792A1 (en) * 1999-02-26 2000-08-26 Genset S.A. Expressed sequence tags and encoded human proteins

Similar Documents

Publication Publication Date Title
JP2006510619A5 (https=)
JP2005512507A5 (https=)
US20200291094A1 (en) Fibronectin type iii domain based scaffold compositions, methods and uses
US6168791B1 (en) Antibodies that bind immunomodulators
US7252971B2 (en) IL-23p40 specific immunoglobulin derived proteins
EP2396011B1 (en) Fibronectin type iii domain based scaffold compositions, methods and uses
EP0966300B1 (en) Treatment of rheumatoid arthritis with antibody anti ifn gamma
IL90990A (en) Pharmaceuticals and diagnostic preparations containing monoclonal antibodies that react with catechin and a series of cells for their production
WO2004003147A2 (en) Cngh0004 polypeptides, antibodies, compositions, methods and uses
WO2005005604A2 (en) Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses
AU2004274390A1 (en) Anti-amyloid antibodies, compositions, methods and uses
WO2006039470A2 (en) Anti- amyloid antibodies, compositions, methods and uses
JP2003507364A5 (https=)
RU97101868A (ru) Иммуномодуляторы
BRPI0113420B1 (pt) Anticorpos para il-1beta humano
US20050266005A1 (en) Methods and compositions for treating IL-3 related pathologies
JP2011500059A (ja) ヒト抗アミロイド抗体、組成物、方法及び使用
JP2012504602A5 (https=)
EP1684703A2 (en) Methods and compositions for treating mcp-1 related pathologies
WO1984004172A1 (en) Monoclonal antibodies to human immune interferon
US20060246070A1 (en) Methods and compositions for treating renal cell carcinoma related pathologies
EP1699486A2 (en) Anti-human lymphotoxin alpha antibodies, compositions, methods and uses
JP2003523186A5 (https=)
WO1995027509A1 (en) Remedy for diseases characterized by abnormal accumulation or activation of leukocyte
CN1056245A (zh) 含有bcrf1拮抗物的药物组合物的制备方法